The Developmental Research Projects are an integral component of the Region VIII RCE. A maximum of five developmental projects funded each year for one year with budgets of up to 100K each. These will likely be high risk projects offering exciting potential for the development of novel approaches, reagents, or models systems that will facilitate the provision of new diagnostics, therapeutics, and vaccines for the nationalbiodefense effort. Developmental projects will also provide critical preliminary data for submission of proposals to funding agencies. These developmental projects will be used to expand the range, scope of the research and also to increase the representation of scientists and institutions involved in the RCE. The MOC will solicit proposals annually from scientists in Region VIII institutions. The RFA will be sent to all RCE participants via the RCE Website, to the members of the Program Guidance Committee, and to the VPRoffice of other Region VIII institutions. These latter two groups will have a unique oversight of all potential RCE participants and programs in their respective institutions and will ensure that developmental projects will be forthcoming from their respective institutions. Each year during the program review, the MOC and Scientific Steering and Review Committee will review both the proposed and existing developmental projects. The most promising projects, which are consistent with the strategic plan and program enhancement of the Region VIII RCE, will be selected for funding. Developmental projects previously funded will be reviewed after one year. If significant new potential forprogram development is presented, the respective developmental project will be considered for establishment as a research project. Those lacking productivity or potential for program development will be discontinued. This process will provide maximum flexibility for RCE program growth and productivity, and will allow the RCE toavail itself of new technologies, talents, and opportunities for program growth and to address specific needs and goals.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI065357-04
Application #
7690448
Study Section
Special Emphasis Panel (ZAI1-KLW-M (M1))
Project Start
2008-05-01
Project End
2009-04-30
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
4
Fiscal Year
2008
Total Cost
$574,411
Indirect Cost
Name
Colorado State University-Fort Collins
Department
Type
DUNS #
785979618
City
Fort Collins
State
CO
Country
United States
Zip Code
80523
Webb, Jessica R; Price, Erin P; Somprasong, Nawarat et al. (2018) Development and validation of a triplex quantitative real-time PCR assay to detect efflux pump-mediated antibiotic resistance in Burkholderia pseudomallei. Future Microbiol 13:1403-1418
York, Joanne; Nunberg, Jack H (2018) A Cell-Cell Fusion Assay to Assess Arenavirus Envelope Glycoprotein Membrane-Fusion Activity. Methods Mol Biol 1604:157-167
Rhodes, Katherine A; Somprasong, Nawarat; Podnecky, Nicole L et al. (2018) Molecular determinants of Burkholderia pseudomallei BpeEF-OprC efflux pump expression. Microbiology 164:1156-1167
Cummings, Jason E; Slayden, Richard A (2017) Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response. PLoS Negl Trop Dis 11:e0005209
Pettey, W B P; Carter, M E; Toth, D J A et al. (2017) Constructing Ebola transmission chains from West Africa and estimating model parameters using internet sources. Epidemiol Infect 145:1993-2002
Furuta, Yousuke; Komeno, Takashi; Nakamura, Takaaki (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93:449-463
Skyberg, Jerod A; Lacey, Carolyn A (2017) Hematopoietic MyD88 and IL-18 are essential for IFN-?-dependent restriction of type A Francisella tularensis infection. J Leukoc Biol 102:1441-1450
Plumley, Brooke A; Martin, Kevin H; Borlee, Grace I et al. (2017) Thermoregulation of Biofilm Formation in Burkholderia pseudomallei Is Disrupted by Mutation of a Putative Diguanylate Cyclase. J Bacteriol 199:
Randall, Linnell B; Georgi, Enrico; Genzel, Gelimer H et al. (2017) Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance. J Antimicrob Chemother 72:1258-1260
Podnecky, Nicole L; Rhodes, Katherine A; Mima, Takehiko et al. (2017) Mechanisms of Resistance to Folate Pathway Inhibitors in Burkholderia pseudomallei: Deviation from the Norm. MBio 8:

Showing the most recent 10 out of 258 publications